Literature DB >> 27716501

Customizing Functionality and Payload Delivery for Receptor-Engineered T Cells.

Christopher A Klebanoff1, Nicholas P Restifo2.   

Abstract

Adoptive immunotherapy using receptor engineering to achieve specific tumor targeting by T cells holds much promise for advancing cancer therapy. Here, two studies by Boice et al. and Roybal et al. provide distinct and potentially complimentary approaches to improve the efficacy and curb potential toxicities of this approach. Published by Elsevier Inc.

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27716501      PMCID： PMC6312703          DOI： 10.1016/j.cell.2016.09.033

Source DB:  PubMed          Journal:  Cell        ISSN： 0092-8674            Impact factor:   41.582


  9 in total

1.  Tumor-specific CD8+ T cells expressing interleukin-12 eradicate established cancers in lymphodepleted hosts.

Authors:  Sid P Kerkar; Pawel Muranski; Andrew Kaiser; Andrea Boni; Luis Sanchez-Perez; Zhiya Yu; Douglas C Palmer; Robert N Reger; Zachary A Borman; Ling Zhang; Richard A Morgan; Luca Gattinoni; Steven A Rosenberg; Giorgio Trinchieri; Nicholas P Restifo
Journal:  Cancer Res       Date:  2010-07-20       Impact factor: 12.701

2.  Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning.

Authors:  Hollie J Pegram; James C Lee; Erik G Hayman; Gavin H Imperato; Thomas F Tedder; Michel Sadelain; Renier J Brentjens
Journal:  Blood       Date:  2012-02-21       Impact factor: 22.113

3.  Loss of the HVEM Tumor Suppressor in Lymphoma and Restoration by Modified CAR-T Cells.

Authors:  Michael Boice; Darin Salloum; Frederic Mourcin; Viraj Sanghvi; Rada Amin; Elisa Oricchio; Man Jiang; Anja Mottok; Nicolas Denis-Lagache; Giovanni Ciriello; Wayne Tam; Julie Teruya-Feldstein; Elisa de Stanchina; Wing C Chan; Sami N Malek; Daisuke Ennishi; Renier J Brentjens; Randy D Gascoyne; Michel Cogné; Karin Tarte; Hans-Guido Wendel
Journal:  Cell       Date:  2016-09-29       Impact factor: 41.582

4.  Prospects for gene-engineered T cell immunotherapy for solid cancers.

Authors:  Christopher A Klebanoff; Steven A Rosenberg; Nicholas P Restifo
Journal:  Nat Med       Date:  2016-01       Impact factor: 53.440

5.  IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T cells.

Authors:  Christopher A Klebanoff; Steven E Finkelstein; Deborah R Surman; Michael K Lichtman; Luca Gattinoni; Marc R Theoret; Navrose Grewal; Paul J Spiess; Paul A Antony; Douglas C Palmer; Yutaka Tagaya; Steven A Rosenberg; Thomas A Waldmann; Nicholas P Restifo
Journal:  Proc Natl Acad Sci U S A       Date:  2004-02-04       Impact factor: 11.205

6.  T-cell mediated rejection of gene-modified HIV-specific cytotoxic T lymphocytes in HIV-infected patients.

Authors:  S R Riddell; M Elliott; D A Lewinsohn; M J Gilbert; L Wilson; S A Manley; S D Lupton; R W Overell; T C Reynolds; L Corey; P D Greenberg
Journal:  Nat Med       Date:  1996-02       Impact factor: 53.440

7.  A synthetic biology framework for programming eukaryotic transcription functions.

Authors:  Ahmad S Khalil; Timothy K Lu; Caleb J Bashor; Cherie L Ramirez; Nora C Pyenson; J Keith Joung; James J Collins
Journal:  Cell       Date:  2012-08-03       Impact factor: 41.582

8.  Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma.

Authors:  Ryan D Morin; Maria Mendez-Lago; Andrew J Mungall; Rodrigo Goya; Karen L Mungall; Richard D Corbett; Nathalie A Johnson; Tesa M Severson; Readman Chiu; Matthew Field; Shaun Jackman; Martin Krzywinski; David W Scott; Diane L Trinh; Jessica Tamura-Wells; Sa Li; Marlo R Firme; Sanja Rogic; Malachi Griffith; Susanna Chan; Oleksandr Yakovenko; Irmtraud M Meyer; Eric Y Zhao; Duane Smailus; Michelle Moksa; Suganthi Chittaranjan; Lisa Rimsza; Angela Brooks-Wilson; John J Spinelli; Susana Ben-Neriah; Barbara Meissner; Bruce Woolcock; Merrill Boyle; Helen McDonald; Angela Tam; Yongjun Zhao; Allen Delaney; Thomas Zeng; Kane Tse; Yaron Butterfield; Inanç Birol; Rob Holt; Jacqueline Schein; Douglas E Horsman; Richard Moore; Steven J M Jones; Joseph M Connors; Martin Hirst; Randy D Gascoyne; Marco A Marra
Journal:  Nature       Date:  2011-07-27       Impact factor: 49.962

9.  Engineering T Cells with Customized Therapeutic Response Programs Using Synthetic Notch Receptors.

Authors:  Kole T Roybal; Jasper Z Williams; Leonardo Morsut; Levi J Rupp; Isabel Kolinko; Joseph H Choe; Whitney J Walker; Krista A McNally; Wendell A Lim
Journal:  Cell       Date:  2016-09-29       Impact factor: 41.582
  9 in total
  2 in total

1.  Modular design of synthetic receptors for programmed gene regulation in cell therapies.

Authors:  Iowis Zhu; Raymond Liu; Julie M Garcia; Axel Hyrenius-Wittsten; Dan I Piraner; Josef Alavi; Divya V Israni; Bin Liu; Ahmad S Khalil; Kole T Roybal
Journal:  Cell       Date:  2022-04-14       Impact factor: 66.850

Review 2.  Engineering chimeric antigen receptor-T cells for cancer treatment.

Authors:  Baixin Ye; Creed M Stary; Xuejun Li; Qingping Gao; Chunsheng Kang; Xiaoxing Xiong
Journal:  Mol Cancer       Date:  2018-02-15       Impact factor: 27.401
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.